Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Louis Excler

Showing results (81-90 of 112) with videos related to

Pageof 12
Sort By:
Plos One|February 19, 2013
Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteersSanjay Mehendale, Madhuri Thakar, Seema Sahay, et al.
IJID Regions|April 3, 2023
Prevalence of HPV infection among Thai schoolgirls in the north-eastern provinces in 2018: implications for HPV immunization policySompong Vongpunsawad, Chulwoo Rhee, Pornjarim Nilyanimit, et al.
Human Vaccines & Immunotherapeutics|December 26, 2024
The long-term impact of vaccine clinical research on national stakeholders involved: Experience from a low-income CountryRejwana Haque Pial, Ganesh Kumar Rai, Rajeev Shrestha, et al.
Plos One|April 28, 2018
Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizationsSiriwat Akapirat, Chitraporn Karnasuta, Sandhya Vasan, et al.
AIDS Research and Human Retroviruses|December 24, 2016
Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination RegimensChitraporn Karnasuta, Siriwat Akapirat, Sirinan Madnote, et al.
Human Vaccines|April 22, 2011
Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectorsHiroto Hara, Hiroto Hara, Takashi Hironaka, et al.
AIDS Research and Human Retroviruses|June 12, 2008
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccineSanjay Mehendale, Jan van Lunzen, Nathan Clumeck, et al.
The Journal of Infectious Diseases|February 25, 2016
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or PolyphosphazeneRobert J O'Connell, Jean-Louis Excler, Victoria R Polonis, et al.
Plos One|December 30, 2011
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in ThailandPunnee Pitisuttithum, Supachai Rerks-Ngarm, Valai Bussaratid, et al.
Vaccine|October 6, 2019
Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary reportMaria Rosario Capeding, Edison Alberto, Arijit Sil, et al.
Pageof 12

Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
Plos One|February 19, 2013
Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteersSanjay Mehendale, Madhuri Thakar, Seema Sahay, et al.
IJID Regions|April 3, 2023
Prevalence of HPV infection among Thai schoolgirls in the north-eastern provinces in 2018: implications for HPV immunization policySompong Vongpunsawad, Chulwoo Rhee, Pornjarim Nilyanimit, et al.
Human Vaccines & Immunotherapeutics|December 26, 2024
The long-term impact of vaccine clinical research on national stakeholders involved: Experience from a low-income CountryRejwana Haque Pial, Ganesh Kumar Rai, Rajeev Shrestha, et al.
Plos One|April 28, 2018
Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizationsSiriwat Akapirat, Chitraporn Karnasuta, Sandhya Vasan, et al.
AIDS Research and Human Retroviruses|December 24, 2016
Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination RegimensChitraporn Karnasuta, Siriwat Akapirat, Sirinan Madnote, et al.
Human Vaccines|April 22, 2011
Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectorsHiroto Hara, Hiroto Hara, Takashi Hironaka, et al.
AIDS Research and Human Retroviruses|June 12, 2008
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccineSanjay Mehendale, Jan van Lunzen, Nathan Clumeck, et al.
The Journal of Infectious Diseases|February 25, 2016
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or PolyphosphazeneRobert J O'Connell, Jean-Louis Excler, Victoria R Polonis, et al.
Plos One|December 30, 2011
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in ThailandPunnee Pitisuttithum, Supachai Rerks-Ngarm, Valai Bussaratid, et al.
Vaccine|October 6, 2019
Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary reportMaria Rosario Capeding, Edison Alberto, Arijit Sil, et al.
Pageof 12